The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
ApexOnco Front Page
Recent articles
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.